Arcus Biosciences Navigates Stock Volatility Amid Focus on Cancer Immunotherapy Development
Arcus Biosciences, a biotech company, focuses on developing immunotherapies for cancer treatment, with a market capitalization of $890.49 million and a complex valuation landscape.
2 minutes to read